

June 25, 2007

Dr. Andrew von Eschenbach
Commissioner, U.S. Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857

Dear Dr. von Eschenbach:

An important new long-term animal feeding study, published in *Environmental Health Perspectives*, from the Cesare Maltoni Cancer Research Center at the European Ramazzini Foundation of Oncology and Environmental Sciences in Italy raises anew serious questions about the safety of the artificial sweetener aspartame.¹

Dose-dependent increases in total malignant tumors, lymphomas/leukemias, and mammary carcinomas were observed in male and/or female rats. At the higher dosage level, the increases were statistically significant for lymphomas/leukemias in both male and female rats, mammary carcinomas in females, and tumor-bearing males. Non-significant increases were observed at the higher dosage for total tumors in males and females and for mammary carcinomas in males and at the lower dosage for total tumors in females, lymphomas/leukemias in males and females, and mammary carcinomas in females. Those non-significant increases would tend to elevate the dose-response trend.

The new study follows up on a study from the same laboratory, but is more sensitive because the rats were exposed to aspartame in utero; in the earlier study the rats were not fed aspartame until they were 8 weeks old. In the new study, groups of animals were exposed from the 12th day in utero to aspartame at levels of 0, 20, or 100 mg/kg bw/day (mg/kg) administered to the pregnant dams and, after weaning, to the animals through their feed. The previous study used those and several additional dosages (4; 500; 2,500; 5,000 mg/kg).² That study found statistically significant increased incidences of leukemias/lymphomas in both male and female rats, malignant schwannomas of peripheral nerves in males, and transitional cell carcinomas of the renal pelvis and ureter and their precursors (dysplasias) in females. Additionally, a few uncommonly occurring brain tumors occurred only in aspartame-treated animals.

The European Food Safety Authority (EFSA) reviewed the study and concluded for various reasons that aspartame was not demonstrated to be carcinogenic.³ While EFSA's rationale may be debated, it must be reconsidered due to the results of the new study.

To put the doses used in the study in context, consider that the Acceptable Daily Intake of aspartame in the United States is 50 mg/kg. The 20 mg/kg dose is equivalent to a 50-

¹ Soffritti M, et al. EHPonline.org (www.ehponline.org/members/2007/10271/10271.pdf, accessed June 13, 2007).

² Soffritti M, et al. *Env Health Persp.* 2006;114:379-85.

³ Opinion of the Scientific Panel on Food Additives, Flavouring, Processing Aids and Materials in Contact with Food. *The EFSA Journal.* 2006;356:1-44.

pound child's drinking about 2½ cans of soda per day and a 150-pound adult's drinking about 7½ cans of soda per day (assuming 175 mg per 12-ounce serving of beverage⁴). The higher dose is equivalent to about 12½ and 37½ cans of soda per day.⁵ The lower dose is something that about 5 percent of American teenagers actually consume.⁶ Obviously, few people drink the larger amounts of aspartame-sweetened soda, but one must presume that lower levels of consumption would lead to increased, but proportionately lower, cancer risks. Of course, increasing exposure to aspartame is the fact that Americans are also consuming aspartame in powdered soft drinks, chewing gum, confections, gelatins, dessert mixes, puddings and fillings, frozen desserts, yogurt, tabletop sweeteners, and some pharmaceuticals such as vitamins and sugar-free cough drops.

In comparison to most animal toxicology studies, the new study has three significant strengths. First, it used more than the usual number of animals per sex/dosage group (95 controls and 70 in each group exposed to aspartame, as compared to the usual 50), thereby increasing the sensitivity of the study. Second, the animals were monitored until they died a natural death (as long as three years), as opposed to most studies, which are terminated after two years (104 weeks). Rats at two years of age are very roughly comparable to people at "retirement age," about 65, whereas three-year-old rats are more equivalent to people 80 to 90 years of age. Thus, the longer experiment sheds light on the effects of aspartame on "elderly" animals. Third, as noted above, the animals were exposed to aspartame during part of their fetal life (ideally, the dams would have been exposed to aspartame prior to pregnancy). In utero exposure reflects human experience and likely increases the sensitivity of the study.

We recognize that the FDA discounted the reliability of the first aspartame study on several grounds, particularly because the sponsor did not provide all the desired data.⁷ Another reason was that transgenic mouse assays done by the National Toxicology Program did not identify problems. However, compared to such short- or medium-term assays and modes-of-action conjectures, chronic animal feeding studies are accepted widely as valid predictors of likely carcinogenic risks for humans: importantly, all acknowledged human carcinogens when tested adequately in animals are also carcinogenic, and many known human carcinogens were first discovered in animals. The FDA also noted that a recent large epidemiology study did not associate aspartame use with cancer. However, that study involved people who did not consume aspartame until they were over 50 years old, and measurement of aspartame consumption was imprecise. The present animal study is much stronger in those respects.

⁴ A Coca-Cola website indicates that a diet soda contains 175 mg of aspartame. (<http://www.beverageinstitute.org/ingredients/pdf/Aspartame.pdf>, accessed June 18, 2007) Other web sites indicate slightly different amounts.

⁵ The quantities of soft drinks would be significantly lower if dosages were calculated on the basis of body surface, as some agencies do, instead of body weight.

⁶ Jacobson M. Liquid Candy—Supplement (Center for Science in the Public Interest, 2005). (http://www.cspinet.org/new/pdf/liquid_candy_final_w_new_supplement.pdf, accessed June 18, 2007)

⁷ FDA-CFSAN. FDA statement on European aspartame study. April 20, 2007. (<http://www.cfsan.fda.gov/~lrd/fpaspar2.html>, accessed June 19, 2007)

In light of the new aspartame study, which extends and corroborates the finding from an earlier study, we urge the FDA to immediately commence a careful review of the new study. Considering how widely aspartame is consumed by young children, as well as adults, in the United States and abroad, it is essential that this review be done as expeditiously as possible. If that review confirms that aspartame caused cancer in the laboratory animals, the FDA must invoke the “Delaney amendment” and revoke its approval for the artificial sweetener.⁸

Sincerely,

Dr. Kamal M. Abdo, PhD
National Institute of Environmental Health Sciences
(retired)*
National Toxicology Program
Bahama, NC 27503

Carlos A. Camargo, Jr., MD, DrPH
Associate Professor of Medicine & Epidemiology
Harvard Medical School
Massachusetts General Hospital
Boston, MA 02114

Devra Davis, PhD, MPH
Director, Center for Environmental Oncology
University of Pittsburgh Cancer Institute
Hillman Cancer Pavillion
Pittsburgh, Pa. 15232

David Egilman MD, MPH
Clinical Associate Professor
Brown University
Attleboro, Massachusetts 02703

Samuel S. Epstein, MD
Professor Emeritus, Environmental & Occupational
Medicine
University of Illinois at Chicago School of Public
Health,
Chairman, Cancer Prevention Coalition
Chicago, Illinois

John Froines, PhD
Director, Center for Occupational and
Environmental Health
University of California, Los Angeles
Los Angeles, CA 90095
Formerly
Director, Toxic Substances, Occupational Safety
and Health Administration
Deputy Director, National Institute for Occupational
Safety and Health

Dale Hattis, PhD
Research Professor
George Perkins Marsh Institute
Clark University
Worcester, MA 01610

Kim Hooper, PhD*
Environmental Chemistry Laboratory
California Department of Toxic Substances Control
California Environmental Protection Agency
Berkeley, CA 94710

James Huff, PhD*
Associate Director for Chemical Carcinogenesis
National Institute of Environmental Health Sciences
Research Triangle Park, NC 27709

Peter F. Infante, DDS, DrPH
Professorial Lecturer
Environmental and Occupational Health
School of Public Health
George Washington University
Washington, DC 20052

Michael F. Jacobson, PhD**
Executive Director
Center for Science in the Public Interest
1875 Connecticut Ave. Suite 300
Washington, DC 20009

formerly:
Director, Office of Standards Review
Health Standards Program
Occupational Safety and Health Administration
U.S. Department of Labor
Washington, DC 20210

⁸ Food, Drug, and Cosmetic Act §409(c)(1)(3)(A).

Daniel Thau Teitelbaum, MD
Adjunct Professor of Environmental Sciences,
Colorado School of Mines
Golden, Colorado 80401
Associate Clinical Professor of Preventive Medicine
University of Colorado Health Sciences at Denver
Denver, Colorado 80202

Joel A. Tickner, ScD
Assistant Professor
Department of Community Health and
Sustainability
Project Director, Lowell Center for Sustainable
Production
University of Massachusetts, Lowell
Lowell, MA 01854

* Affiliations listed for identification purposes only.

** Please respond via Dr. Jacobson at 1875 Connecticut Ave., #300, Washington, DC
20009